<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00113776</url>
  </required_header>
  <id_info>
    <org_study_id>20030194</org_study_id>
    <nct_id>NCT00113776</nct_id>
  </id_info>
  <brief_title>Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer</brief_title>
  <official_title>A Multicenter, Open-label, Single Arm Clinical Trial to Determine the Safety of ABX-EGF Extended Therapy in Subjects With Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the safety of ABX-EGF administered as monotherapy in
      subjects with metastatic colorectal cancer who were previously randomized to best supportive
      care (BSC) in protocol 20020408 and subsequently determined to have progressive disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Lab values</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of HAHA formation</measure>
  </primary_outcome>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABX-EGF</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Subject previously randomized to BSC in protocol 20020408 and
        subsequently determined to have progressive disease - ECOG performance status of 0, 1 or 2
        - Adequate hematologic, renal and hepatic function Exclusion Criteria: - Myocardial
        infarction in time interval between completing 20020408 and enrollment in study - History
        or evidence of interstitial pneumonitis or pulmonary fibrosis - Prior anti-tumor therapies
        including prior experimental agents or approved anti-tumor small molecules and biologics
        during the time interval between completing 20020408 protocol and enrollment in this study
        - Use of systemic chemotherapy or radiotherapy during the time interval between completing
        20020408 protocol and enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Portugal</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <link>
    <url>http://www.vectibix.com/</url>
    <description>FDA-approved Drug Labeling</description>
  </link>
  <results_reference>
    <citation>Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W, Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008 Jan;19(1):92-8. Epub 2007 Sep 4.</citation>
    <PMID>17785764</PMID>
  </results_reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2005</study_first_submitted>
  <study_first_submitted_qc>June 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2005</study_first_posted>
  <last_update_submitted>January 20, 2011</last_update_submitted>
  <last_update_submitted_qc>January 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Metastatic Colorectal Cancer, Colon</keyword>
  <keyword>Colorectal, Rectal Cancer, EGFr</keyword>
  <keyword>Metastatic, Cancer, ABX-EGF</keyword>
  <keyword>Panitumumab, Clinical Trial</keyword>
  <keyword>Immunex, Abgenix, Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

